GERON ENROLLS FIRST PATIENT IN DRUG STUDY FOR ESSENTIAL THROMBOCYTHEMIA
MPNRF | January 3, 2011
January 2011
Geron Corporation has enrolled their first person in a Phase 2 clinical trial to test their drug (GRN163L) in patients with essential thrombocythemia. These drugs are aiming to target the leukemic stem cell, which Geron believes will “impact the biology of the disease”. This Phase 2 trial is testing the safety and efficacy of the drug.